Literature DB >> 27904700

Detection of gene copy number alterations in DCIS and invasive breast cancer by QM-FISH.

Aifeng Pan1, Yawei Zhou2, Kun Mu1, Yansong Liu3, Feifei Sun1, Peng Li4, Li Li1.   

Abstract

The exact roles of copy number alteration (CNA) in initiation, progression and immunotherapy of breast cancer and the genomic alterations behind progression from ductal carcinoma in situ (DCIS) to invasive carcinoma remain unknown. Quantitative multi-gene fluorescence in situ hybridization (QM-FISH) opens a possibility of large scale genomic analysis of specific deletions and amplifications with high-resolution at one cell level. We detected CNAs of 30 genes using QM-FISH and analyzed their association with clinicopathological parameters and patients' outcomes in 66 breast cancers with synchronous invasive carcinoma and DCIS. The copy numbers of 30 genes in DCIS and the invasive area in all tumors were compared. The results revealed some recurrent CNAs including amplifications of MDMx, CCNE2, HER2 and deletions in Chek1, p53, Rb1 with a frequency of over 20%. By comparing the CNAs in invasive tumors and co-occurring DCIS, the similarity of chromosomal instability (CIN) in both components was visualized. Some co-occurrence patterns of CNAs of 30 genes were observed. The study also demonstrated higher frequencies of occurrence of CNAs in aneuploidy tumors, high grade tumors and tumors with high proliferation index. Higher CNAs were also found in death patients. Overall, we uncovered some frequently occurring gene aberrations out of 30 genes and synchronous pre-invasive lesions share majority of CNAs with invasive breast cancer. Moreover QM-FISH is a powerful technique to detect CNAs of multi-genes and give more information on co-occurrence of CNAs.

Entities:  

Keywords:  Breast cancer; chromosomal instability; copy number alteration; ductal carcinoma in situ; quantitative multi-gene fluorescence in situ hybridization

Year:  2016        PMID: 27904700      PMCID: PMC5126342     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  24 in total

Review 1.  Genome-wide copy number analysis in primary breast cancer.

Authors:  Takayuki Ueno; Mitsuru Emi; Hidenori Sato; Noriko Ito; Mariko Muta; Katsumasa Kuroi; Masakazu Toi
Journal:  Expert Opin Ther Targets       Date:  2012-02-08       Impact factor: 6.902

2.  Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas.

Authors:  H. Blegen; N. Einhorn; K. Sjövall; A. Roschke; B. M. Ghadimi; L. M. McShane; B. Nilsson; K. Shah; T. Ried; G. Auer
Journal:  Int J Gynecol Cancer       Date:  2000-11       Impact factor: 3.437

3.  A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.

Authors:  Torsten O Nielsen; Joel S Parker; Samuel Leung; David Voduc; Mark Ebbert; Tammi Vickery; Sherri R Davies; Jacqueline Snider; Inge J Stijleman; Jerry Reed; Maggie C U Cheang; Elaine R Mardis; Charles M Perou; Philip S Bernard; Matthew J Ellis
Journal:  Clin Cancer Res       Date:  2010-09-13       Impact factor: 12.531

Review 4.  The genetics and genomics of cancer.

Authors:  Allan Balmain; Joe Gray; Bruce Ponder
Journal:  Nat Genet       Date:  2003-03       Impact factor: 38.330

Review 5.  Molecular evolution of breast cancer.

Authors:  Peter T Simpson; Jorge S Reis-Filho; Theodora Gale; Sunil R Lakhani
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

Review 6.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Authors:  Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

Review 7.  Genetic instabilities in human cancers.

Authors:  C Lengauer; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

8.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

9.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

10.  Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine.

Authors:  Linping Hu; Kun Ru; Li Zhang; Yuting Huang; Xiaofan Zhu; Hanzhi Liu; Anders Zetterberg; Tao Cheng; Weimin Miao
Journal:  Biomark Res       Date:  2014-02-05
View more
  3 in total

Review 1.  Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.

Authors:  Vidya C Sinha; Helen Piwnica-Worms
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

Review 2.  Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.

Authors:  Kevin Shee; Kristen E Muller; Jonathan Marotti; Todd W Miller; Wendy A Wells; Gregory J Tsongalis
Journal:  Am J Pathol       Date:  2018-10-29       Impact factor: 4.307

3.  Diversity index as a novel prognostic factor in breast cancer.

Authors:  Yul Ri Chung; Hyun Jeong Kim; Young A Kim; Mee Soo Chang; Ki-Tae Hwang; So Yeon Park
Journal:  Oncotarget       Date:  2017-09-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.